Compare AORT & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AORT | PRCT |
|---|---|---|
| Founded | 1984 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 1993 | 2021 |
| Metric | AORT | PRCT |
|---|---|---|
| Price | $43.48 | $30.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | $49.36 | ★ $51.13 |
| AVG Volume (30 Days) | 304.0K | ★ 1.1M |
| Earning Date | 02-23-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $422,646,000.00 | $299,907,000.00 |
| Revenue This Year | $15.97 | $48.30 |
| Revenue Next Year | $10.96 | $29.44 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 9.81 | ★ 50.07 |
| 52 Week Low | $21.97 | $27.80 |
| 52 Week High | $48.25 | $79.29 |
| Indicator | AORT | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 40.55 | 41.81 |
| Support Level | $41.82 | $29.62 |
| Resistance Level | $45.99 | $35.20 |
| Average True Range (ATR) | 1.38 | 1.60 |
| MACD | -0.28 | -0.29 |
| Stochastic Oscillator | 33.07 | 15.92 |
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.